

1-1-2017

Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma

ŞAFAK AKIN

DUYGU YAZGAN AKSOY

SERKAN AKIN

MEHMET KILIÇ

FAHRİ YETİŞİR

See next page for additional authors

Follow this and additional works at: <https://journals.tubitak.gov.tr/medical>



Part of the [Medical Sciences Commons](#)

Recommended Citation

AKIN, ŞAFAK; AKSOY, DUYGU YAZGAN; AKIN, SERKAN; KILIÇ, MEHMET; YETİŞİR, FAHRİ; and BAYRAKTAR, MİYASE (2017) "Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma," *Turkish Journal of Medical Sciences*: Vol. 47: No. 6, Article 9. <https://doi.org/10.3906/sag-1702-99>

Available at: <https://journals.tubitak.gov.tr/medical/vol47/iss6/9>

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.

Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma

Authors

ŞAFAK AKIN, DUYGU YAZGAN AKSOY, SERKAN AKIN, MEHMET KILIÇ, FAHRİ YETİŞİR, and MİYASE BAYRAKTAR

Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma

Şafak AKIN^{1*}, Duygu YAZGAN AKSOY², Serkan AKIN³, Mehmet KILIÇ⁴, Fahri YETİŞİR⁵, Miyase BAYRAKTAR¹

¹Department of Endocrinology and Metabolism, Faculty of Medicine, Hacettepe University, Ankara, Turkey

²Department of Internal Medicine, Faculty of Medicine, Acıbadem University, İstanbul, Turkey

³Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

⁴Department of General Surgery, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey

⁵Medicana Hospital, Clinic of General Surgery, Ankara, Turkey

Received: 16.02.2017 • Accepted/Published Online: 02.07.2017 • Final Version: 19.12.2017

Background/aim: The purpose of this study was to analyze the clinicopathological characteristics of patients with papillary thyroid carcinoma (PTC) and papillary thyroid microcarcinoma (PTMC) and predictive factors for central lymph node metastasis (CLNM).

Materials and methods: Patients diagnosed as having PTC and PTMC were evaluated. Clinical and laboratory parameters were recorded.

Results: The mean age at diagnosis was 47.3 ± 11.9 years. Of all 223 patients, 91 (40.8%) had lymph nodes removed, 29 of whom had lymph node metastasis and 24 of whom had only CLNM. Univariate analysis revealed that central lymph node metastasis was associated with male sex, presence of bilaterality, presence of extrathyroidal extension, and tumor size ($P = 0.033$, $P = 0.027$, $P < 0.001$, $P < 0.001$, respectively). However, multivariate logistic regression analysis showed that sex, age, tumor size, multifocality, bilaterality, extrathyroidal extension, clinical suspicion, and chronic lymphocytic thyroiditis were not significantly correlated with an increased risk for CLNM.

Conclusion: Lymph node metastasis is known to be a significant predictor of locoregional recurrence in patients with PTC and PTMC. Further prospective studies are needed to identify the extent of surgery such as central lymph node dissection in patients with PTC or PTMC.

Key words: Papillary thyroid microcarcinoma, central lymph node metastasis

1. Introduction

Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid gland. Papillary thyroid microcarcinoma (PTMC) is a subtype of PTC defined as PTC with a maximum tumor diameter of 10 mm or less (1). Several studies have reported that PTMC is determined in up to 35.6% of autopsy materials, and up to 37.3% of PTMCs are associated with cervical lymph node metastasis (1–3). In recent years, the number of patients with PTMC has been increasing because of the use of high-resolution ultrasonography (USG) and fine-needle aspiration biopsy. Despite the fact that PTMC is usually associated with good prognosis, regional lymph node metastasis is not uncommon (4). Moreover, several studies have demonstrated lymph node metastases at presentation, locoregional recurrence during follow-up, and rarely

distant metastases and even cancer-related deaths (5–8). Central lymph node metastasis (CLNM) is frequently diagnosed with microscopic lymph node metastasis in surgical specimens. In PTMC, the prevalence of subclinical CLNM has been detected as 30%–65% (4,9,10). Previous studies suggested the use of prophylactic central lymph node dissection (CLND) in patients with PTMC (11,12); however, this approach remains a controversial matter. Therefore, determination of predictive factors for CLNM is important to avoid unnecessary CLND in patients with PTMC. To improve the diagnostic accuracy in PTMC, many authors used a combination of clinicopathologic and USG characteristics. Therefore, the purpose of this study was to investigate the predictive factors for CLNM among a group of patients with surgically proven PTMC or PTC.

* Correspondence: safakcavus@gmail.com

2. Materials and methods

2.1. Study population

We conducted a retrospective study involving 223 patients with PTC who underwent definitive primary surgical therapy between January 2010 and December 2014. All patients had no history of thyroid or neck surgery for nonthyroidal cancer, as well as no neck irradiation. Medical records and radiologic and pathologic reports were analyzed. Papillary thyroid carcinoma measuring 10 mm or less in diameter was classified as PTMC. Data collected included age, sex, preoperative clinical suspicion of cancer based on USG findings, tumor size, multifocality, bilateral disease, chronic lymphocytic thyroiditis, extrathyroidal extension, central or lateral lymph nodes with metastatic carcinoma, and type of surgery (thyroidectomy with or without central lymph node dissection). Tumor size was defined as the largest dimension. Multifocality was defined as more than 1 focus of tumor within the thyroid. Bilateral tumors were defined as tumors existing in both thyroid lobes.

2.2. Statistical analysis

The statistical analyses were performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA). Normally distributed data are expressed as mean \pm SD and were compared using the t-test. Categorical variables are expressed as percentage and were compared using the chi-square test or Fisher's exact test as appropriate. Nonparametric variables were analyzed using the Mann-Whitney U test. In the statistical analyses, $P < 0.05$ was considered significant.

3. Results

The study population included 223 patients, the majority whom were female (173, 77.6%). The mean age at diagnosis was 47.3 ± 11.9 years (range: 17–77 years) and 124 (55.6%) patients were aged more than 45 years. Table 1 lists the clinical and pathologic characteristics between the PTC and PTMC groups.

A total of 208 (93.3%) patients underwent total or near total thyroidectomy, and 15 (6.7%) had a lobectomy followed by a complete thyroidectomy at a later date.

Ninety-one (40.8%) of the 223 patients had lymph nodes removed, 86 had central lymph nodes only removed, 3 had lateral lymph nodes only removed, and 2 had both central and lateral lymph nodes removed. Of these 91 patients, 29 had lymph node metastasis and 24 had only central lymph node metastasis (CLNM).

Of the 88 patients who had central lymph nodes removed, 26 (29.5%) had CLNM. Univariate analysis revealed that central lymph node metastasis was associated with male sex, presence of bilaterality, presence

of extrathyroidal extension, and tumor size ($P = 0.033$, $P = 0.027$, $P < 0.001$, $P < 0.001$, respectively). However, the multivariate logistic regression analysis showed that sex, age, tumor size, multifocality, bilaterality, extrathyroidal extension, clinical suspicion, and chronic lymphocytic thyroiditis were not significantly correlated with an increased risk for CLNM (Table 2).

Among the 141 patients with PTMC, 47 had only CLND, 7 (14.9%) of whom had CLNM. Twenty-six patients had CLNM, 19 had PTC, and 7 had PTMC. There was a significant difference in CLNM between patients with PTC and PTMC ($P < 0.001$).

4. Discussion

Differentiated thyroid carcinoma is the most common endocrine malignancy. We investigated clinical and pathologic features in patients with PTC and PTMC. PTMC is considered an indolent disease that has excellent prognosis with a mortality of about 1% and recurrence or persistence of only 1.4%–10.5% (4,5,13–15). On the other hand, the potential aggressiveness of PTMC has been reported in some studies (5–7,16).

The treatment for PTMC continues to be a topic of debate in the literature. Some authors choose complete thyroidectomy plus lymph node dissection, whereas others choose observation in the event of a solitary PTMC found incidentally on lobectomy/thyroidectomy (17). Central lymph node metastasis is still a risk in patients with PTC or PTMC; we found that 29.5% of all patients had CLND. Despite the fact that many studies have shown that lymph node metastasis in PTMC is one of the main predictors of recurrence (18–20), there is no consensus as to whether prophylactic neck dissection should be routinely included in the surgical treatment. The American Thyroid Association guidelines recommend inclusion of neck dissection for PTC only in the setting of clinically evident lymph node metastasis (21). However, the reported incidence of lymph node metastasis in PTC has ranged widely from 20% to 90% (22). Routine prophylactic CLND might be associated with significantly higher morbidities, such as recurrent laryngeal nerve injury and hypoparathyroidism (23,24). CLND can be achieved with low morbidity by experienced thyroid surgeons (25,26).

In our study, male sex, tumor size, age, multifocality, extrathyroidal extension, clinical suspicion, and chronic lymphocytic thyroiditis were not predictive of CLNM. Vorasubin et al. (27) recently demonstrated that large, multifocal, and capsularly or lymphovascularly invasive PTMC was significantly associated with at least a 1.93 times greater risk of metastasizing than were smaller, solitary, and noninvasive tumors. Another study by Siddiqui et al. (28) showed that younger age (age < 45 years), multifocality,

Table 1. Patient characteristics.

Variable	PTMC (n = 141)	PTC (n = 82)	P
Sex, n (%)			
Female	116 (67.1)	57 (32.9)	0.028
Male	25 (50.0)	25 (50.0)	
Age at diagnosis, years, mean \pm SD	48.2 \pm 10.9	45.8 \pm 13.4	0.148
Age, n (%)			
\leq 45 years	56 (56.6)	43 (43.4)	0.065
>45 years	85 (68.5)	39 (31.5)	
Tumor size, mm (range)	0.5 (0.1–1.0)	2.0 (1.1–8.5)	
Multifocality, n (%)			
Absent	100 (70.9)	51 (62.2)	0.179
Present	41 (29.1)	31 (37.8)	
Bilaterality, n (%)			
Absent	116 (82.3)	56 (68.3)	0.017
Present	25 (17.7)	26 (31.7)	
Chronic lymphocytic thyroiditis, n (%)			
Absent	104 (73.8)	65 (79.3)	0.354
Present	37 (26.2)	17 (20.7)	
Extrathyroidal extension, n (%)			
Absent	130 (92.2)	64 (78.0)	0.002
Present	11 (7.8)	18 (22.0)	
Clinical suspicion on preoperative USG, %			
Unsuspected	61.0	64.4	0.708
Suspected	39.0	35.6	
Central lymph node dissection, n (%)			
Absent	94 (66.7)	41 (50.0)	0.014
Present	47 (33.3)	41 (50.0)	
Central lymph node metastasis, n (%)			
Absent	134 (95.0)	63 (76.8)	<0.001
Present	7 (5.0)	19 (23.2)	

and extrathyroidal extension were predictors of CLNM. Our data showed that male sex and tumor size were not predictive for CLNM, in contrast to findings by others (18,29,30). In addition, Siddiqui et al. reported that the risk of lymph node metastasis in incidental PTMC was not significantly different compared with known/suspected PTC (28). Therefore, physicians must be aware of central

or lateral lymph node metastasis when planning treatment for PTMC.

The limitation to our study is the small number of overall patients and the small number of patients with resected lymph nodes. In addition, we did not analyze data from the long-term follow-up period such as disease recurrence and disease-free survival.

Table 2. Multivariate logistic regression analysis for clinical and pathologic features predictive of CLNM.

Risk predictor	CLNM		
	OR	95% CI	P-value
Age	0.912	0.772–1.078	0.280
Sex	0.949	0.093–9.703	0.964
Tumor size	1.841	0.673–5.039	0.235
Multifocality	0.581	0.046–7.404	0.676
Bilaterality	0.220	0.014–3.538	0.286
Chronic lymphocytic thyroiditis	3.233	0.338–30.92	0.308
Extrathyroidal extension	0.331	0.017–6.372	0.464
Clinical suspicion	0.194	0.016–2.390	0.201

In conclusion, PTMC can metastasize to central or lateral lymph nodes. Lymph node metastasis is known as a significant predictor of locoregional recurrence. Further

prospective studies are needed to identify the extent of surgery such as CLND in patients with PTC or PTMC.

References

- Baloch ZW, LiVolsi VA. Microcarcinoma of the thyroid. *Adv Anat Pathol* 2006; 13: 69-75.
- Zhao Q, Ming J, Liu C, Shi L, Xu X, Nie X, Huang T. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. *Ann Surg Oncol* 2013; 20: 746-752.
- Wang Y, Li L, Wang YX, Feng XL, Zhao F, Zou SM, Hao YZ, Ying JM, Zhou CW. Ultrasound findings of papillary thyroid microcarcinoma: a review of 113 consecutive cases with histopathologic correlation. *Ultrasound Med Biol* 2012; 38: 1681-1688.
- Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H, Takanashi Y. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. *Ann Surg* 2003; 237: 399-407.
- Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid—prognostic significance of lymph node metastasis and multifocality. *Cancer* 2003; 98: 31-40.
- Kuo EJ, Goffredo P, Sosa JA, Roman SA. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. *Thyroid* 2013; 23: 1305-1311.
- Ghossein R, Ganly I, Biagini A, Robenshtok E, Rivera M, Tuttle RM. Prognostic factors in papillary microcarcinoma with emphasis on histologic subtyping: a clinicopathologic study of 148 cases. *Thyroid* 2014; 24: 245-253.
- Kim TY, Hong SJ, Kim JM, Kim WG, Gong G, Ryu JS, Kim WB, Yun SC, Shong YK. Prognostic parameters for recurrence of papillary thyroid microcarcinoma. *BMC Cancer* 2008; 8: 296.
- Roh JL, Kim JM, Park CI. Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. *Ann Surg Oncol* 2008; 15: 2482-2486.
- So YK, Son YI, Hong SD, Seo MY, Baek CH, Jeong HS, Chung MK. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. *Surgery* 2010; 148: 526-531.
- Hyun SM, Song HY, Kim SY, Nam SY, Roh J.L, Han MW, Choi SH. Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid microcarcinoma. *Ann Surg Oncol* 2012; 19: 591-596.
- Zhang L, Liu Z, Liu Y, Gao W, Zheng C. The clinical prognosis of patients with cN0 papillary thyroid microcarcinoma by central neck dissection. *World J Surg Oncol* 2015; 13: 138.
- Pakdaman MN, Rochon L, Gologan O, Tamilia M, Garfield N, Hier MP, Black MJ, Payne RJ. Incidence and histopathological behavior of papillary microcarcinomas: study of 429 cases. *Otolaryng Head Neck* 2008; 139: 718-722.
- Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, Cailleux AF, Lumbroso JD, Parmentier C, Schlumberger M. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. *Cancer* 1998; 83: 553-559.

15. Noguchi S, Yamashita H, Murakami N, Nakayama I, Toda M, Kawamoto H. Small carcinomas of the thyroid. A long-term follow-up of 867 patients. *Arch Surg-Chicago* 1996; 131: 187-191.
16. Malandrino P, Pellegriti G, Attard M, Violi MA, Giordano C, Sciacca L, Regalbuto C, Squatrito S, Vigneri R. Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. *J Clin Endocr Metab* 2013; 98: 1427-1434.
17. Lim YC, Choi EC, Yoon YH, Kim EH, Koo BS. Central lymph node metastases in unilateral papillary thyroid microcarcinoma. *Brit J Surg* 2009; 96: 253-257.
18. Liu Z, Wang L, Yi P, Wang CY, Huang T. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a meta-analysis. *Int J Clin Exp Pathol* 2014; 7: 932-937.
19. Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. *Endocr J* 1999; 46: 209-216.
20. Pisanu A, Reccia I, Nardello O, Uccheddu A. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. *World J Surg* 2009; 33: 460-468.
21. Hartl DM, Travagli JP. The updated American Thyroid Association Guidelines for management of thyroid nodules and differentiated thyroid cancer: a surgical perspective. *Thyroid* 2009; 19: 1149-1151.
22. Lee SH, Lee SS, Jin SM, Kim JH, Rho YS. Predictive factors for central compartment lymph node metastasis in thyroid papillary microcarcinoma. *Laryngoscope* 2008; 118: 659-662.
23. Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. *Thyroid* 2009; 19: 683-689.
24. Carling T, Long WD, Udelsman R. Controversy surrounding the role for routine central lymph node dissection for differentiated thyroid cancer. *Curr Opin Oncol* 2010; 22: 30-34.
25. Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. *Laryngoscope* 2009; 119: 1135-1139.
26. Sancho JJ, Lennard TW, Paunovic I, Triponez F, Sitges-Serra A. Prophylactic central neck dissection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). *Langenbeck Arch Surg* 2014; 399: 155-163.
27. Vorasubin N, Nguyen C, Wang M. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a meta-analysis. *Ear Nose Throat J* 2016; 95: 73-77.
28. Siddiqui S, White MG, Antic T, Grogan RH, Angelos P, Kaplan EL, Cipriani NA. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. *Thyroid* 2016; 26: 807-815.
29. Zhang L, Wei WJ, Ji QH, Zhu YX, Wang ZY, Wang Y, Huang CP, Shen Q, Li DS, Wu Y. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. *J Clin Endocr Metab* 2012; 97: 1250-1257.
30. Yang Y, Chen C, Chen Z, Jiang J, Chen Y, Jin L, Guo G, Zhang X, Ye T. Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma. *Clin Endocrinol* 2014; 81: 282-288.